Merck KGaA Announces CHMP Opinion for Cladribine Tablets in Multiple Sclerosis

27-Sep-2010 - Germany

Merck KGaA announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion regarding the marketing authorization application (MAA) for Cladribine Tablets as a treatment for relapsing-remitting multiple sclerosis (MS). The CHMP is of the opinion that based on currently available data the benefits of Cladribine Tablets do not outweigh its risks. Merck is committed to making Cladribine Tablets available to MS patients in Europe and is evaluating all options to gain approval in the European Union, including a potential appeal to request re-examination of the submission by the CHMP, in accordance with the current European regulatory legislation.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances